Delcath's chemotherapy agent gets orphan drug statusReutersAug 31 (Reuters) - Delcath Systems Inc (DCTH.O) said US health regulators granted an orphan drug status to doxorubicin, a chemotherapy agent, for the treatment of primary liver cancer, sending its shares up 48 percent. The company said it tested ...FDA Grants Delcath Orphan-Drug Status For DoxorubicinNASDAQMarket Report -- In Play (DCTH)MSN MoneyDelcath Systems treatment gets special FDA statusThe Business InsiderReuters India -PR Newswire (press release)all 21 news articles »